Outlook Therapeutics Connects with Investors at Upcoming Virtual Event
ISELIN, N.J. — Outlook Therapeutics, Inc. (Nasdaq: OTLK) has been making waves in the biopharmaceutical field with its groundbreaking ocular therapy. This marks an exciting era for the company following the recent approval of its eye treatment formulation of bevacizumab, which targets wet age-related macular degeneration (wet AMD).
CEO Russell Trenary to Share Company Insights
Russell Trenary, the President and CEO of Outlook Therapeutics, is set to engage with investors during the Virtual Investor Closing Bell Series scheduled for mid-September. His goal is to provide insightful information about the company’s direction and its ongoing projects.
Event Overview and Question-and-Answer Session
During this event, Mr. Trenary will present a thorough corporate overview, highlighting the company’s future plans. After his detailed presentation, there will be an opportunity for a live question-and-answer session. He encourages participants to ask questions, aiming to address as many as possible within the given time.
How to Access the Live Webcast
The event will be available through a live video webcast, which encourages broader participation. Attendees can access the webcast through the company’s investor relations page, and it will be accessible for 90 days after the event. This presents a great chance for stakeholders to hear directly from company leadership.
Focus on Wet AMD Treatment
Outlook Therapeutics is committed to advancing its lead product, LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma). This product is notable as the first-ever ophthalmic formulation of bevacizumab and has received marketing authorization in the European Union and the UK for treating wet AMD.
Plans for LYTENAVA™ Commercial Launch
The company is gearing up to officially launch LYTENAVA™ in these markets within the first half of the next calendar year, further demonstrating its dedication to tackling important health challenges facing patients.
Future Research and FDA Applications
Outlook Therapeutics is also actively pursuing studies for the treatment of wet AMD in the United States. Currently, the product is undergoing a rigorous evaluation in a non-inferiority study. If the results are promising, the company plans to resubmit a biologics license application (BLA) to the FDA, aiming for the first approval of an ophthalmic formulation for retinal applications.
Company Overview
Outlook Therapeutics is committed to developing and commercializing innovative therapies that target significant ocular conditions. With recent regulatory achievements, the company is positioning itself as a key player in the biopharmaceutical industry.
Contacting the Investor Relations Team
If you have inquiries regarding investment opportunities, Jenene Thomas, the Chief Executive Officer of JTC Team, LLC, is available at 833.475.8247. You can also reach out via email to OTLK@jtcir.com.
Frequently Asked Questions
What is the purpose of the Virtual Investor Closing Bell Series?
This series is designed to provide updates and insights about companies to investors, allowing them to engage directly with the company’s leadership.
Who is the CEO of Outlook Therapeutics?
Russell Trenary is the President and CEO of Outlook Therapeutics, leading the company’s vision and strategy.
What product is Outlook Therapeutics currently promoting?
The company is primarily focused on LYTENAVA™ (bevacizumab-vikg), which is aimed at treating retinal diseases, especially wet AMD.
When do they plan to launch LYTENAVA™ commercially?
LYTENAVA™ is slated for commercial launch in the European Union and the UK during the first half of next year.
How can investors get in touch with Outlook Therapeutics?
Investors can reach out to JTC Team, LLC, by contacting Chief Executive Officer Jenene Thomas via phone or email for any inquiries they may have.
